Share

NRX Pharmaceuticals Inc. - news published 285 - readings 2.525

BACK
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (Form 8-K)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update ● Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of N ...

Continue reading
21.03.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

- Conference call to take place at 8:30am ET - WILMINGTON, Del. , March 12, 2025 / PRNewswire / -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 1 ...

Continue reading
12.03.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10 th -12 th WILMINGTON, Del. , Feb. 6, 2025 / PRNewswire / -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, ...

Continue reading
06.02.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition (Form 8-K)

HOPE Therapeutics ™ , Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition ● $25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOP ...

Continue reading
03.02.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt (Form 8-K)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt ● This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics ● Investment consists of $3.5 million in above the market ...

Continue reading
29.01.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt

This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics Investment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026 WILMINGTON, Del. , Jan. 28, 2025 / PRNewswire / -- NRx Pharmaceuticals, Inc. (N ...

Continue reading
28.01.2025
NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement (Form 8-K)

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement ● Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement ● Nasdaq stated that the m ...

Continue reading
22.01.2025